Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2009 | 1 |
2012 | 1 |
2014 | 2 |
2015 | 1 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
Profile of elotuzumab and its potential in the treatment of multiple myeloma.
Blood Lymphat Cancer. 2014 Jun;2014(4):15-27. doi: 10.2147/BLCTT.S49780.
Blood Lymphat Cancer. 2014.
PMID: 26005365
Free PMC article.
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.
Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F.
Szmania S, et al.
J Immunother. 2015 Jan;38(1):24-36. doi: 10.1097/CJI.0000000000000059.
J Immunother. 2015.
PMID: 25415285
Free PMC article.
Clinical Trial.
Item in Clipboard
Clinical grade purification and expansion of natural killer cells.
Lapteva N, Szmania SM, van Rhee F, Rooney CM.
Lapteva N, et al.
Crit Rev Oncog. 2014;19(1-2):121-32. doi: 10.1615/critrevoncog.2014010931.
Crit Rev Oncog. 2014.
PMID: 24941378
Free PMC article.
Review.
Item in Clipboard
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.
Garg TK, Szmania SM, Khan JA, Hoering A, Malbrough PA, Moreno-Bost A, Greenway AD, Lingo JD, Li X, Yaccoby S, Suva LJ, Storrie B, Tricot G, Campana D, Shaughnessy JD Jr, Nair BP, Bellamy WT, Epstein J, Barlogie B, van Rhee F.
Garg TK, et al.
Haematologica. 2012 Sep;97(9):1348-56. doi: 10.3324/haematol.2011.056747. Epub 2012 Mar 14.
Haematologica. 2012.
PMID: 22419581
Free PMC article.
Item in Clipboard
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, Shaughnessy JD Jr, Barlogie B, Yaccoby S, Afar DE.
van Rhee F, et al.
Mol Cancer Ther. 2009 Sep;8(9):2616-24. doi: 10.1158/1535-7163.MCT-09-0483. Epub 2009 Sep 1.
Mol Cancer Ther. 2009.
PMID: 19723891
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite